Chromos, Glenmark deal

Glenmark acquired two preclinical humanized MAbs from CHR. CHR-1103 binds to integrin alpha(2)beta(1) ( VLA-2) and is expected to begin Phase I testing treat acute multiple sclerosis (MS) next year. ...